Serotonin transporter and 5-hydroxytryptamine receptor 1A (SERT/5-HT1A)

The serotonin transporter (SERT) and 5-hydroxytryptamine receptor 1A (5-HT1A) system is a multimodal therapeutic target primarily utilized in the treatment of major depressive disorder (MDD). SERT, encoded by the SLC6A4 gene, is a monoamine transporter that regulates serotonin levels by facilitating its reuptake from the synapse into the presynaptic neuron (UniProt: P31645). The 5-HT1A receptor, encoded by the HTR1A gene, is a G protein-coupled receptor that acts as an inhibitory autoreceptor on serotonergic neurons and a postsynaptic receptor in brain regions like the hippocampus (UniProt: P08908). Drugs targeting this dual system, known as Serotonin Partial Agonist and Reuptake Inhibitors (SPARIs), aim to enhance serotonergic neurotransmission more effectively than traditional SSRIs. By combining SERT inhibition with 5-HT1A partial agonism, these agents can bypass the negative feedback loop that normally limits serotonin release during the early stages of treatment (Stahl, 2011, PMID: 21548715). This pharmacological profile is intended to provide robust antidepressant efficacy with a potentially improved side-effect profile regarding sexual dysfunction (Artigas, 2013, PMID: 23219458).

Other names

Serotonin transporter / 5-HT1A-associated uptake systemSLC6A4 and HTR1ASPARI target5-HTT and 5-HT1A receptorSerotonin transporter and 5-HT1A receptor

Simultaneous inhibition of the serotonin transporter (SERT) to increase synaptic serotonin and partial agonism of the 5-hydroxytryptamine receptor 1A (5-HT1A) to desensitize presynaptic autoreceptors (Stahl, 2011, PMID: 21548715).